Illumina and Labcorp expand precision oncology testing collaboration

Reuters

Mar 18

<a href="https://laohu8.com/S/ILMN">Illumina</a> and Labcorp expand precision oncology testing collaboration

Illumina and Labcorp expanded their collaboration to advance precision oncology using next-generation sequencing solutions. The companies plan projects to broaden access to cancer biomarker testing through distributed test offerings and to generate evidence to support payer coverage. They will explore co-commercializing Labcorp’s FDA-authorized liquid biopsy assay PGDx elio plasma focus Dx with Illumina’s FDA-approved TruSight Oncology Comprehensive for solid tumor profiling. Illumina and Labcorp also plan to develop new in vitro diagnostic tests for comprehensive genomic profiling and whole-genome sequencing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2620594572"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620594572\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620594572?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620594572","market":"nz","top_or_hot":-1,"title":"Illumina and Labcorp expand precision oncology testing collaboration","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> and Labcorp expand precision oncology testing collaboration\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Illumina and Labcorp expanded their collaboration to advance precision oncology using next-generation sequencing solutions. The companies plan projects to broaden access to cancer biomarker testing through distributed test offerings and to generate evidence to support payer coverage. They will explore co-commercializing Labcorp’s FDA-authorized liquid biopsy assay PGDx elio plasma focus Dx with Illumina’s FDA-approved TruSight Oncology Comprehensive for solid tumor profiling. Illumina and Labcorp also plan to develop new in vitro diagnostic tests for comprehensive genomic profiling and whole-genome sequencing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ILMNV\">Illumina Inc</a>. published the original content used to generate this news brief on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina and Labcorp expand precision oncology testing collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina and Labcorp expand precision oncology testing collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> and Labcorp expand precision oncology testing collaboration\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Illumina and Labcorp expanded their collaboration to advance precision oncology using next-generation sequencing solutions. The companies plan projects to broaden access to cancer biomarker testing through distributed test offerings and to generate evidence to support payer coverage. They will explore co-commercializing Labcorp’s FDA-authorized liquid biopsy assay PGDx elio plasma focus Dx with Illumina’s FDA-approved TruSight Oncology Comprehensive for solid tumor profiling. Illumina and Labcorp also plan to develop new in vitro diagnostic tests for comprehensive genomic profiling and whole-genome sequencing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ILMNV\">Illumina Inc</a>. published the original content used to generate this news brief on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0006061336.USD","symbol_name":"Blackrock US Small and MidCap Opportunities A2 USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4YTpTd:1","article_id":"2620594572","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620594572","pubTimestamp":1773840024,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Illumina and Labcorp expanded their collaboration to advance precision oncology using next-generation sequencing solutions. The companies plan projects to broaden access to cancer biomarker testing through distributed test offerings and to generate evidence to support payer coverage. They will explore co-commercializing Labcorp’s FDA-authorized liquid biopsy assay PGDx elio plasma focus Dx with Illumina’s FDA-approved TruSight Oncology Comprehensive for solid tumor profiling. Illumina and Labcorp also plan to develop new in vitro diagnostic tests for comprehensive genomic profiling and whole-genome sequencing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief on","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","BK4121":"生命科学工具和服务","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU0251142724.SGD":"Fidelity America A-SGD","BK4550":"红杉资本持仓","BK4588":"碎股","ILMN":"Illumina","BK4196":"保健护理服务","BK4535":"淡马锡持仓","LH":"徕博科","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4534":"瑞士信贷持仓","LU0742534661.SGD":"Fidelity America A-SGD (hedged)"},"translate_title":"Illumina和Labcorp扩大精准肿瘤检测合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":0.9,"LH":0.9},"content_text":"Illumina and Labcorp expand precision oncology testing collaboration\n    \n\n        Illumina and Labcorp expanded their collaboration to advance precision oncology using next-generation sequencing solutions. The companies plan projects to broaden access to cancer biomarker testing through distributed test offerings and to generate evidence to support payer coverage. They will explore co-commercializing Labcorp’s FDA-authorized liquid biopsy assay PGDx elio plasma focus Dx with Illumina’s FDA-approved TruSight Oncology Comprehensive for solid tumor profiling. Illumina and Labcorp also plan to develop new in vitro diagnostic tests for comprehensive genomic profiling and whole-genome sequencing.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief on March 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}